Cipla : Q4FY17 Results
Amir Shaikh / 25 May 2017
The company's total sales for Q4FY17 came in at Rs 3487 crore, which represents a 2.2 per cent sequential decline and 7.2 per cent YoY increase.
The company's total sales for Q4FY17 came in at Rs 3487 crore, which represents a 2.2 per cent sequential decline and 7.2 per cent YoY increase.
Its operating loss for the quarter amounted to Rs 220.9 crore, as against operating profit of Rs 336.32 crore in Q3FY17.
The company reported net loss of Rs 61.79 crore, as against net profit of Rs 374.8 crore in Q3FY17.
During Q4FY17, the company has commenced commercial production at its newly-built formulation facility in Sikkim.
The stock today opened at Rs 525 and touched intra-day low of Rs 497.40 on the BSE.
The board of directors has recommended dividend of Rs 2 per equity share on the face value of Rs 2 each.
Cipla Ltd is an Indian pharmaceutical company which exports raw materials, intermediates, prescription drugs, OTC products and veterinary products. It also offers technology for products and processes.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.